European Association for Vision and Eye Research 2014

Article

European Association for Vision and Eye Research, EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences.

European Association for Vision and Eye Research, EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences.

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the members module, on www.ever.be

The annual meeting EVER 2014 will take place in Nice, France from Oct 1-4, 2014.

Besides the free papers and posters, there will be keynote lectures, special interest symposia (SIS), courses and workshops, with many distinguished invited speakers.

The abstracts of EVER 2014 will be published in the EVER journal, Acta Ophthalmologica.

Useful web links:
Meeting overview.
Information about the congress
Details on congress registration
Early registration deadline is September 1.

Contact: Marlene Verlaeckt, Executive Officer

marlene.verlaeckt@ever.be

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.